1

1 Chronic Overlapping Pain Conditions and Nociplastic Pain

- 2 Keira J.A. Johnston¹*, Rebecca Signer², Laura M. Huckins¹**
- 3 1. Department of Psychiatry, Yale School of Medicine, Yale University, New Haven,
- 4 CT 06511, USA
- 5 2. Department of Genetic and Genomic Sciences, Icahn School of Medicine at
- 6 Mount Sinai, New York City, NY 10029, USA
- 7 3. Corresponding authors. *keira.johnston@yale.edu **<u>laura.huckins@yale.edu</u>
- 8

2

10 Abstract

11 Chronic Overlapping Pain Conditions (COPCs) are a subset of chronic pain conditions 12 commonly comorbid with one another and more prevalent in women and assigned 13 female at birth (AFAB) individuals. Pain experience in these conditions may better fit 14 with a new mechanistic pain descriptor, nociplastic pain, and nociplastic type pain may 15 represent a shared underlying factor among COPCs. We applied GenomicSEM 16 common-factor genome wide association study (GWAS) and multivariate transcriptome-17 wide association (TWAS) analyses to existing GWAS output for six COPCs in order to 18 find genetic variation associated with nociplastic type pain, followed by genetic 19 correlation (linkage-disequilibrium score regression), gene-set and tissue enrichment 20 analyses. We found 24 independent single nucleotide polymorphisms (SNPs), and 127 21 unique genes significantly associated with nociplastic type pain, and showed nociplastic 22 type pain to be a polygenic trait with significant SNP-heritability. We found significant 23 genetic overlap between multisite chronic pain and nociplastic type pain, and to a 24 smaller extent with rheumatoid arthritis and a neuropathic pain phenotype. Tissue enrichment analyses highlighted cardiac and thyroid tissue, and gene set enrichment 25 26 analyses emphasized potential shared mechanisms in cognitive, personality, and 27 metabolic traits and nociplastic type pain along with distinct pathology in migraine and 28 headache. We use a well-powered network approach to investigate nociplastic type 29 pain using existing COPC GWAS output, and show nociplastic type pain to be a 30 complex, heritable trait, in addition to contributing to understanding of potential 31 mechanisms in development of nociplastic pain.

3

33 Background

Chronic pain can be defined as pain that persists 3+ months¹ and is a main symptom of 34 35 many conditions as well as being associated with injury and surgery. Chronic pain can 36 also be studied as a complex disease trait as evidenced by large recent genome wide association studies (GWAS)²⁻⁷. Recently, the International Association for the Study of 37 38 Pain (IASP) also redefined pain and 'chronic primary pain' codes for the International Classification of Diseases 11th Edition (ICD-11)^{8–10}. More than 1 in 5 US adults 39 experience chronic pain¹¹, and chronic pain is associated with high socioeconomic and 40 quality of life burden ^{1,12}, and despite genetic studies into chronic pain as a disease trait. 41 42 and on conditions where chronic pain is a prominent symptom, mechanisms of 43 development of chronic pain are not fully understood.

44

Neuropathic and nociceptive pain¹³ are used to categorize pain and chronic pain 45 according to suspected or confirmed underlying mechanism(s). Neuropathic pain is 46 defined as being caused by lesions or disease in the somatosensory nervous system, 47 48 and nociceptive pain, designed to directly contrast neuropathic pain, is defined as pain 49 arising from actual or threatened damage to non-neural tissue (in the context of a 50 normally functioning somatosensory nervous system). However, pain experienced in the 51 context of many different chronic pain conditions may not fit with these two descriptors -Chronic Overlapping Pain Conditions (COPCs)^{14–16} may represent a subset of chronic 52 pain conditions where pain experiences very often diverge from nociceptive/ 53 neuropathic or a mixed nociceptive/ neuropathic pain state. COPCs are a subset of 54 55 chronic pain conditions commonly comorbid with one another and more prevalent in

4

56 people assigned female at birth (AFAB). The United States congress and the National 57 Institutes of Health (NIH) listed ten conditions as COPCs; myalgic encephalitis/ chronic 58 fatigue syndrome (ME/CFS), vulvodynia, temporomandibular disorders, irritable bowel 59 syndrome (IBS), interstitial cystitis/ painful bladder syndrome, fibromyalgia, 60 endometriosis, chronic tension-type headache, chronic migraine headache, and chronic 61 low-back pain. In these conditions, there may not be actual or threatened tissue damage or lesion/ disease at the somatosensory nervous system (e.g., fibromyalgia), or 62 63 if features of nociceptive/ neuropathic pain are present they do not fully capture the pain 64 experience (e.g., chronic low back pain). A proposed third mechanistic pain descriptor, 'nociplastic pain', added to IASP terminology ¹³ in 2017 may better capture features of 65 pain in COPCs ¹⁴. 66

67

68 Nociplastic pain is defined as pain arising from altered nociception in the absence of 69 clear lesion/ disease of the somatosensory nervous system and/or absence of actual or 70 threatened tissue damage. Pain in COPCs, where nociplastic pain could be the underlying mechanism (or main underlying mechanism if a mixed pain state is 71 72 suspected), may fit better with this description as many COPCs are not associated with 73 neural/ non-neural tissue damage (e.g., fibromyalgia), or if disease and tissue damage 74 are present pain is often non-proportional to tissue damage and can be diffuse 75 throughout the body beyond diseased tissue sites (e.g., endometriosis, chronic low back 76 pain). Nociplastic pain is also associated, compared to nociceptive or neuropathic pain, with greater risk of CNS-related symptoms such as fatigue, changes in cognition and 77 memory, depression, anxiety, and sleep issues as also commonly seen in COPCs¹⁵. 78

5

79

80 These features of COPCs, combined with the fact they are commonly comorbid with 81 one another, may suggest that nociplastic type pain is an underlying shared factor 82 across COPCs. Even in COPCs where a mixed pain state with nociceptive pain (i.e., 83 where tissue damage may be present) such as endometriosis, studies have shown that 84 nociplastic pain contributes significantly to pain experience, and is associated with 85 severity of pain independent of surgical procedures, amount of endometriosis, body mass index, and age ¹⁷. Previous studies also suggest COPCs could be viewed as a 86 single "lifelong" disease that "manifests in different bodily regions over time" ¹⁸. There 87 are epidemiological studies of pelvic pain conditions (e.g., MAPP^{19,20}), but there are no 88 89 GWAS of vulvodynia, chronic pelvic pain, or bladder pain syndrome/ IC. In addition, 90 there are to date no sufficiently large studies with both genotyping and guestionnaire 91 data designed specifically to ascertain nociplastic pain (such as the Central Sensitization Inventory²¹ or Nociplastic-Based Fibromyalgia Features tool²²). However, 92 93 large-scale GWAS for several other COPCs are available, and can be studied as a 94 network to uncover genetic variation associated with nociplastic-type pain as an 95 underlying factor in all COPCs.

96

97 Chronic pain conditions can be highly stigmatized ²³⁻²⁷ – this is likely even more
98 common in COPCs due to a lack of or disproportionate-to-pain-level presence of tissue
99 or nerve damage ²⁸⁻³⁰, and higher prevalence of COPCs in women and AFAB people
100 ^{23,31}. Understanding mechanisms of chronic pain that are not due to, or cannot be fully
101 explained by, nervous system damage or dysfunction or tissue damage (i.e., nociplastic

6

102 pain) will contribute to legitimizing the pain experience in COPCs. In addition, finding 103 genetic variation associated with nociplastic pain could inform new treatment 104 approaches in COPCs, conditions where many existing pharmaceutical and surgical treatments can be less effective ³² or even actively worsen pain ³³ compared to use in 105 106 nociceptive/ neuropathic pain. 107

108 Methods

109

110 **GWAS** summary statistics

111 GWAS summary statistics for 6 chronic overlapping pain condition (COPC) traits were 112 obtained through publicly available downloads, requests made directly to study authors, 113 or through data request to FinnGenn (release R9, May 2023). Traits, sample sizes, and sources are summarized in Table 1, and include chronic widespread pain², low back 114 pain ³⁴. broad headache ³⁵, temporomandibular joint disorder ³⁶, and irritable bowel 115 syndrome ³⁷. We opted not to include migraine or ME/CFS summary statistics. With 116 ME/CFS ³⁸ this is due to sample size being too small for successful completion of the 117 118 multivariable LDSC step of GenomicSEM common-factor GWAS analysis (Ncase = 427, 119 Ncontrol = 972), and because genotyping in this study was performed using the Illumina 120 Immunochip array (i.e., not whole-genome genotyping, but a specialized assay focused 121 on immune-relevant SNPs). For migraine, a significant proportion of the 'broad 122 headache' GWAS case participants are likely migraineurs and/or have both tension-type 123 headache and migraine, therefore including the broad headache GWAS but not

7

124 migraine GWAS allows for capturing a fuller spectrum of headache and migraine-

associated genetic variation, without over-representation of migraine.

126 For each trait excluding endometriosis, GWAS samples are at least partially, and in

some cases completely, comprised of UK Biobank participants and samples may

- 128 overlap –sample overlap is permitted and does not statistically bias GenomicSEM
- 129 analyses ^{39,40}.
- 130
- 131 Table 1
- 132

133 **Common factor GWAS**

134 GenomicSEM was used to carry out a common-factor GWAS. First, we prepared

135 (munged) GWAS summary statistics using 'munge' function included in GenomicSEM.

136 Sum of effective sample sizes was calculated for low back pain (LBP) and IBS, as these

137 represented GWAS meta-analyses of case-control phenotypes ⁴¹. Briefly, variants with

138 info values <= 0.9, minor allele frequency (MAF) <= 0.01, that were not SNPs with

139 missing values, that were strand ambiguous, those with duplicated rsIDs, those without

a match in the HapMap 3 SNP file used for quality control, and those with mismatched

allele labels compared to the HapMap 3 SNP file were removed. Next, multivariable

142 linkage disequilibrium (LD)- score regression was carried out to produce matrices used

143 in the common-factor GWAS step. GenomicSEM 'sumstats' function was used for a

144 final preparation step, jointly processing the GWAS summary statistics files for each of

the 6 traits included in the analysis. This function merges across all summary statistics

146 using listwise deletion, performs quality control (including backing out logistic betas,

8

147 checking for allele mismatches, missing data, and duplicate variants), and merges with 148 the reference SNP file. Output from multivariable LD-score regression and from 149 GenomicSEM 'sumstats' is taken forward to common factor GWAS using GenomicSEM 150 'commonFactorGWAS' function. Our chosen common-factor model, where the single 151 latent factor represents 'nociplastic type pain', is shown in Figure 1. 152 153 Figure 1 154 155 First, we fitted the common-factor GWAS model without SNP effects and noted loadings 156 of each trait onto the singular factor (Figure 1). These were significant (Table 2, p < p157 0.05) and model fitting was successful, so we proceeded to fitting the model including 158 SNP effects with 'smooth_check=T'. We note that TMJ variance standard error is very 159 large (Figure 1, SE = 3.8), likely due to the small case number in the TMJ GWAS, but 160 factor loading was significant (Table 2, 0.69, p < 0.05) so we elected to include TMJ in 161 this model. Output produced from the above model is equivalent to GWAS summary 162 statistics (magnitude of association between each SNP and a trait of interest) for the 163 latent factor onto which the 6 traits load – which we describe as nociplastic-type pain. 164 Next, we calculate an estimated sample size for the 'GWAS' of nociplastic-type pain 165 according to instruction provided on the GenomicSEM github, first reserving SNP 166 results for SNPs with MAF <= 0.4 and => 0.1, and then calculating \hat{N} according to the 167 formula for each SNP:

 $\frac{1}{\left(2*MAF*\left(1-MAF\right)\right)*SE^{2}}$

168

Equation 1: Formula to estimate per-SNP sample size for SNPs included in common-factor GWAS

9

- 169
- 170
- 171 Taking the mean of this set of values then gives \hat{N} . For nociplastic-type pain \hat{N}
- 172 =578,561.3 (where this sample size is necessary in calculations e.g., LD-score
- 173 regression analyses for genetic correlation, we use the value 578,561).

174 Table 2

175

176 **Defining significant, independent SNPs**

177 Common-factor GWAS output (nociplastic type pain summary statistics) was then taken

178 forward and analyzed within FUMA (Functional Mapping and Annotation of Genome-

179 Wide Association Studies) ⁴², a web-based suite of tools for downstream GWAS

analyses. Genome-wide significant, independent SNPs were defined using FUMA as

181 SNPs associated with nociplastic pain factor ($p < 5x10^{-8}$) and independent from one

182 another ($r^2 < 0.6$).

183

184 LD-score Regression

We used 'ldsc' ^{40,43} to estimate SNP-heritability of nociplastic-type pain, and to estimate genetic correlation between nociplastic-type pain and three pain-related phenotypes; multisite chronic pain (MCP), a measure of number of chronic pain sites, rheumatoid arthritis, a chronic pain condition that is not usually considered a COPC and where pain for a majority of individuals is likely mainly nociceptive/ inflammatory ^{44,45}, and a neuropathic pain phenotype ⁴⁶.

10

192 Multisite chronic pain vs nociplastic-type pain

- ¹⁹³ We obtained summary statistics for GWAS of multisite chronic pain (MCP) ³, a general
- 194 chronic pain phenotype previously found to be heritable, polygenic, and significantly
- associated with gene expression changes in the brain through download from University
- 196 of Glasgow Enlighten (research data repository). MCP summary statistics were munged
- as previously described, using 'ldsc' package, as was common factor GWAS output for
- 198 nociplastic-type pain. We then carried out LD-score regression, estimating genetic
- 199 correlation between MCP and nociplastic-type pain.
- 200

201 Rheumatoid arthritis vs nociplastic-type pain

202 We obtained rheumatoid arthritis GWAS summary statistics from a recent large GWAS

 $(N = 311, 292)^{47}$ from GWAS Catalog ⁴⁸. As previously described and again using

204 'ldsc', we calculated genetic correlation between nociplastic type pain and rheumatoid205 arthritis.

206

207 Neuropathic vs nociplastic-type pain

208 We obtained GWAS summary statistics for a study on neuropathic pain susceptibility

- 209 ($N_{effective} = 16,311.72$) by request to the study authors ⁴⁶, using 'ldsc' as previously
- 210 described to calculate genetic correlation between nociplastic-type pain and neuropathic
- 211 pain.
- 212
- 213 Multivariate Transcriptome-Wide Association Study

11

214	An extension of GenomicSEM common-factor GWAS is multivariate (common-factor)
215	TWAS. Here, FUSION TWAS 49 output for each of the 6 COPCs serves as input (as
216	GWAS summary statistics did for common-factor GWAS in GenomicSEM common-
217	factor GWAS). We performed TWAS in each of the 6 COPC traits using GWAS
218	summary statistics and the FUSION package and scripts, and using pre-computed
219	predictive models for all 49 Genotype-Tissue Expression project (GTEx) 50 v8 tissues 51 .
220	We used models including genes with significant heritability and with weights calculated
221	using all genetic ancestries, as recommended for typical analyses and to increase
222	sensitivity. FUSION output (TWAS summary statistics for each of the 6 COPCs) was
223	prepared using the GenomicSEM 'read_fusion' function, and then taken forward with
224	multivariable LDSC output from previous common-factor GWAS analysis to perform
225	common-factor TWAS.
226	
227	Significant gene-tissue association findings were defined at the tissue-wide and
228	experiment-wide level, through Bonferroni multiple testing correction across all tests
229	within a tissue and across all genes tested across all tissues respectively.
230	
231	Specific and Non-Specific Genes

As part of multivariate GWAS and TWAS analyses, a Q (heterogeneity) value is
calculated per SNP-trait association (or per gene-tissue-trait association), indicating
degree of heterogeneity (i.e., the proportion of gene expression or SNP association
effect that is mediated through pathways other than the shared common factor). Genes
specific to nociplastic-type pain were identified through subsetting multivariate TWAS

12

237	output to include genes in significant (tissue-wide) gene-tissue associations and with
238	non-significant Q p values (i.e., non-significant heterogeneity). Non-specific genes were
239	also identified as above but with significant Q p values. Q p values were Bonferroni-
240	corrected for multiple testing within-tissue. ($Qp_{Bonferroni} = Qp/N$ tests in that tissue).
241	
242	
243	Tissue enrichment analyses
244	We carried out binomial tests of enrichment within our TWAS results to investigate
245	whether certain tissues showed a higher proportion of tissue-wide significant ($P_{Bonferroni}$
246	< 0.05) associations results than expected by chance, and whether certain tissues
247	showed higher proportion of nominally significant (P < 0.05) associations than expected
248	by chance. Genes tested per tissue are available from FUSION predictor models ⁴⁹ .
249	
250	Gene-set enrichment analyses
251	Gene-set enrichment analyses on all tissue wide significant genes, on tissue wide
252	significant and specific genes ($Qp_{Bonferroni} > 0.05$), and on tissue wide significant non-
253	specific genes ($Qp_{Bonferroni} < 0.05$) was carried out using FUMA, with all genes tested in
254	multivariate TWAS and with recognized Ensembl gene ID as background (N = 26455
255	genes).
256	

1	2
L	3
_	-

258	Results
259	
260	Common-factor GWAS
261	We fitted a common factor GWAS model (including individual SNP effects), using data
262	for six COPC traits (CWP, LBP, endometriosis, TMJ, IBS, and broad headache). This
263	model estimates the size of association between SNPs and a latent common factor
264	(nociplastic type pain), producing results effectively equivalent to a standard GWAS of
265	this unmeasured latent factor. We found a total of 663 SNPs across fifteen GWAS
266	genomic risk loci significantly associated with nociplastic-type pain (p < 5 x 10 $^{-8}$,
267	Figure 2), consisting of 24 independent SNPs. The majority of these SNPs (18/24) have
268	not been previously associated with pain-related traits (Table S2).
269	
270	Figure 2
271	
272	Heritability and Genetic Correlation
273	We estimated the SNP-based heritability of the nociplastic type pain trait using output
274	from our GenomicSEM common-factor GWAS. We also estimated genetic correlation

275 between nociplastic type pain and another complex chronic pain trait, multisite chronic

pain, between nociplastic type pain and RA, a disease where chronic pain is a common 276

277 symptom but is likely associated with nociceptive rather than nociplastic pain

mechanisms^{44,45}, and between nociplastic-type pain and neuropathic pain. Nociplastic-278

279 type pain was found to be significantly heritable (liability scale SNP-h2 = 0.025, SE =

280 0.0014), and was significantly genetically correlated with MCP (rg = 0.92, SE= 0.04) and

267

14

to a much lesser degree with rheumatoid arthritis (rg = 0.18, SE = 0.04). Neuropathic and nociplastic-type pain were also significantly genetically correlated (rg = 0.79, SE = 0.099).

284

285 The LD-score regression intercept values when calculating these genetic correlations

was close to 1 (0.97-1.03), suggesting the majority of genomic inflation captured by

lambda GC (estimates ranging 1.0025-1.3) is due to polygenicity rather than populationstructure.

289

290 Multivariate TWAS

291 To explore nociplastic type pain at the transcriptomic level and uncover tissue-level 292 gene expression relevant to this trait, we carried out a common-factor TWAS analysis of 293 6 COPC traits using GenomicSEM. We found 819 tissue-wide significant gene-tissue 294 associations consisting of 127 unique genes, across all 49 tested GTEx tissues. As part 295 of multivariate GWAS and TWAS analyses with GenomicSEM, a Q (heterogeneity) 296 value is calculated per association. This value indicates degree of heterogeneity (i.e., 297 the proportion of gene expression or SNP association effect that is mediated through 298 pathways other than the shared common factor, across the traits included in the model 299 that load onto the common factor). Specific genes were identified through subsetting 300 multivariate TWAS output to include genes in significant (tissue-wide) gene-tissue 301 associations and with non-significant Q p values (i.e., non-significant heterogeneity). 302 Non-specific genes were also identified as above but with significant Q p values. Q p

15

303	values were Bonferroni-corrected for multiple testing within-tissue. ($Qp_{Bonferroni} = Qp/N$
304	tests in that tissue).

306	450 of the 819 tissue-wide significant gene-tissue associations showed significant
307	heterogeneity ($Qp_{Bonferroni} < 0.05$), and the remaining 369 did not ($Qp_{Bonferroni} > 0.05$).
308	Twenty-eight unique genes showed significant heterogeneity across all tested tissues
309	($Qp_{Bonferroni} < 0.05$), and 94 showed non-significant heterogeneity ($Qp_{Bonferroni} > 0.05$).
310	Five genes showed both significant and non-significant heterogeneity depending on
311	tissue, and were excluded from gene-set enrichment tests of specific/ heterogeneous
312	genes.
313	
314	Tissue enrichment
315	To determine whether specific tissues showed more or fewer significant TWAS results
316	than expected by chance, we carried out a series of binomial tests for enrichment of
317	significant TWAS results within each tested tissue. We found that 9 of the 49 tested
318	tissues showed a different proportion of significant gene-tissue TWAS findings than
319	expected by chance. Cultured fibroblasts, atrial appendage of the heart, tibial nerve,
320	and thyroid were enriched for significant associations, whereas amygdala, substantia
321	nigra, Epstein-Barr-virus-transformed lymphocytes, terminal ileum of the small intestine
322	and vagina showed significantly fewer significant associations than expected. At the
323	nominal significance level (unadjusted $P < 0.05$), two tissues showed a different
324	proportion of associations than expected by chance – whole blood and skeletal muscle
325	were enriched for significant (unadjusted $P < 0.05$) associations.

16

-2	\mathbf{a}	6
J	4	υ

327 Gene-set enrichment

- 328 To explore potential mechanisms in nociplastic pain that are shared with other complex
- 329 traits of interest, we performed three sets of gene-set enrichment tests using FUMA.
- 330 First, we used all unique tissue-wide significant gene findings from multivariate TWAS,
- then a subset of those findings that showed significant heterogeneity (non-specific
- 332 genes) and finally a subset with non-significant heterogeneity (specific genes).
- 333

334 **Tissue-wide significant genes**

- 335 Of 127 unique genes, 120 had a recognized ensemble gene ID within FUMA and were
- included in analyses. Eight positional gene sets were enriched (adjusted p < 0.05) for
- nociplastic-type-pain associated genes; chr17q21, chr3p21, chr9q33, chr16q22,
- 338 chr12q13, chr2q34, chr4q33, and chr1q21. Kyoto Encyclopedia of Genes and Genomes
- 339 (KEGG) pathway gene set nitrogen metabolism was also enriched for nociplastic pain
- 340 genes, as was chemical and genetic perturbation gene set 'SU_LIVER' (genes
- 341 specifically upregulated in the liver). A total of 44 GWAS Catalog traits including
- 342 cognitive function (adjusted $p = 1.76 \times 10^{-10}$), extremely high intelligence (adjusted $p = 1.76 \times 10^{-10}$)
- 343 3.3x10⁻⁹), sleep duration (adjusted $p = 5.95x10^{-9}$), and headache (adjusted $p = 1.10x10^{-9}$)
- ³⁴⁴ ⁸) were enriched for nociplastic-type pain genes (Table S3, Figure 3A). Additional gene
- 345 sets enriched for nociplastic pain genes including microRNA target sets, transcription
- 346 factor target sets, computational gene sets and cancer gene modules can be found in
- 347 Table S4.
- 348

17

347

Figure 3

351

352 Specific genes

353 90 of 94 tissue-wide significant genes without significant heterogeneity across all

- 354 tissues where a significant association was found, and with an ensembl gene ID
- 355 recognized within FUMA were included in this analysis. We found seven positional gene
- 356 sets to be enriched for specific nociplastic pain genes, including chr3p21, chr9q33,
- 357 chr16q22, chr2q34, chr4q33, chr12q13, and chr1q21. Chemical and genetic

perturbation gene set 'SU_LIVER' (adjusted $p = 4.45 \times 10^{-3}$) was enriched for specific

nociplastic pain genes, as was nitrogen metabolism (adjusted p = 0.01), and the

hallmark gene set fatty acid metabolism (adjusted p = 0.018). Additional gene sets

361 enriched for specific nociplastic pain genes are listed at Table S5. We found 28 GWAS

- 362 Catalog traits enriched for specific nociplastic pain genes (Table S6, Figure 3B),
- including extremely high intelligence (adjusted $p = 8.02 \times 10^{-10}$), sleep duration (adjusted

 $p = 1.09 \times 10^{-9}$), regular attendance at a religious group (adjusted p = 2.77 \times 10^{-9}), and

365 cognitive function (adjusted $p = 3.08 \times 10^{-7}$).

366 Non-specific genes

367 25 of 28 tissue-wide significant genes with significant heterogeneity across tissues 368 where a significant association was found, and with an ensembl gene ID recognized 369 within FUMA were included in this analysis. Positional gene sets chr17q21, and chr6q16 370 were enriched for these non-specific nociplastic pain genes, as were several cancer 371 gene neighborhoods (Table S7) and 9 GWAS Catalog traits including migraine without

- aura (adjusted $p = 9.31 \times 10^{-7}$), headache (adjusted $p = 1.79 \times 10^{-6}$), and migraine
- 373 (adjusted $p = 7.63 \times 10^{-5}$) (Table S8, Figure 3C).
- 374
- 375 There was no overlap in gene sets enriched for specific and non-specific genes, and
- 376 migraine and headache gene sets were enriched for non-specific nociplastic-type pain
- 377 genes only.

19

378 **Discussion**

379 We carried out common-factor GWAS and TWAS analyses incorporating six COPCs to 380 investigate genetic variation associated with nociplastic type pain, a mechanistic pain 381 descriptor and type of pain likely important across COPCs. This method allows us to 382 find genetic variation associated with nociplastic type pain in the absence of a dataset 383 where genotype data and phenotype information on nociplastic type pain are available 384 together. Furthermore, if nociplastic type pain is a shared factor among COPCs, then 385 our findings are likely relevant to COPCs where GWAS are currently unavailable and/ or 386 could not be included here, such as interstitial cystitis, vulvodynia, and ME/CFS. We 387 found that nociplastic type pain is a moderately heritable trait (observed SNP-h2 0.025) 388 with similar SNP heritability to rheumatoid arthritis (RA liability scale SNP-h2 = 0.07, 389 observed SNP-h2 = 0.035). Our findings indicate that nociplastic type pain is a complex. 390 polygenic trait, and we found 24 independent SNPs significantly associated with this 391 trait.

392

393 Nociplastic type pain is genetically correlated with rheumatoid arthritis and MCP 394 We observed extremely high genetic correlation between nociplastic type pain and MCP 395 (rq = 0.92). Individuals with a non-zero trait value for MCP could as a group be majority 396 composed of individuals with COPCs – to assess this we carried out a series of Fisher's 397 exact tests on counts of COPC ICD10 code occurrences within and outside of MCP 398 'cases' (MCP trait value >=1) in UK Biobank (see Table S9). We found that for ICD10 399 category codes for COPCs that were available in UK Biobank (back pain, post-viral 400 fatigue (ME/CFS), migraine, IBS, endometriosis and tension headache), all were

20

401	significantly overrepresented in MCP cases compared to those without chronic pain
402	(MCP trait value 0), with the most over-represented COPC being fibromyalgia (OR
403	4.48), considered a prototypical nociplastic pain condition. However, we also tested for
404	enrichment of rheumatoid arthritis (a non-COPC pain condition) cases, and again found
405	significant enrichment (Table S9). This suggests high phenotypic overlap in COPCs and
406	MCP in UK Biobank cannot fully explain high genetic correlation values of our
407	nociplastic pain factor and MCP.
408	Another explanation for high nociplastic pain factor-MCP genetic correlation may be that
409	a large amount of genetic variation associated with the main characteristic of MCP
410	(increasing number of sites of chronic pain) is also captured in a GWAS/ GWAS-
411	equivalent analysis of nociplastic type pain – a recent paper outlining clinical criteria in
412	assessing and grading nociplastic pain lists regional (as opposed to discrete) location
413	and spread of pain as a key characteristic of nociplastic pain ⁵² . Additionally, diagnostic
414	criteria in RA include (chronic) pain in at least 2 or more large joints, which may
415	generate the significant phenotypic overlap between RA and MCP in UK Biobank –
416	however in RA this 'increasing number of sites' characteristic is driven by disease-
417	specific processes, resulting in low genetic correlation between RA and nociplastic pain
418	factor, and between RA and MCP.
410	

419

Neuropathic pain was also relatively highly genetically correlated with nociplastic-type
pain (rg = 0.79) – however this rg value is significantly less than 1, indicating a
significant portion of genetic variation is distinct between these two pain traits. In
addition, a high degree of genetic correlation between nociplastic type and neuropathic

21

424	pain, to a greater extent than rg with nociceptive pain types, could be expected. In their
425	recent review on nociplastic pain, Fitzcharles et al emphasize not only how common
426	mixed pain states are (pain with nociceptive/neuropathic/nociplastic features), but that
427	neuropathic features in hip and knee arthritis and low back pain observed in studies
428	predating the concept of nociplastic pain likely represent nociplastic etiology ¹⁴ .
429	Neuropathic features of pain in various rheumatic diseases have also been suggested
430	to actually represent nociplastic pain 53.
431	
432	Traits enriched for specific and non-specific nociplastic-type pain genes indicate
433	distinct pathology of migraine and headache
434	Gene set enrichment results showed certain genes significantly contribute to variation in
435	nociplastic pain phenotype, but that a large amount of their influence on COPC traits is
436	not mediated by nociplastic type pain (non-specific genes i.e., genes with significant
437	heterogeneity in genomicSEM analyses). GWAS trait gene sets enriched for such
438	genes included migraine and headache, suggesting involvement of factors outside of

439 nociplastic pain in these traits. Non-nociplastic-type-pain-specific genes were also

440 enriched in trait gene sets for male-pattern baldness (androgenic alopecia) – alopecia,

441 including androgenic alopecia, has been previously associated with drugs that block

442 CGRP (calcitonin gene related peptide), a treatment for acute migraine and migraine
 443 prevention ⁵⁴.

444

445 **Potential metabolic and liver related pathology in nociplastic pain**

22

446 GWAS trait gene sets enriched for specific nociplastic type pain genes included amino 447 acid and acylcarnitine levels. Changes in amino acid levels are associated with fibromyalgia, migraine, osteoarthritis and complex regional pain syndrome ⁵⁵. High 448 449 acylcarnitine levels can indicate disorders in fatty acid metabolism, and diets high in 450 certain fatty acids have been associated with increased allodynia in rodent models, and associated with human chronic pain conditions ⁵⁶. Lipids generally are also involved in 451 acute and chronic inflammation ⁵⁷ and changes to acylcarnitine metabolism are 452 453 observed in dementia, certain cancers, heart failure and coronary artery disease ⁵⁸. 454 Changes to circulating lipids have also been observed in COPCs including fibromyalgia, headache, migraine, TMD, low back pain and IBS ⁵⁹, and cholesterol metabolism in 455 microglia has been linked to neuropathic pain in a rodent model ⁶⁰. In addition, certain 456 457 drug therapies used in treatment for systemic lupus erythematosus and rheumatoid arthritis can disrupt lipid metabolism ⁶¹, and experiencing chronic pain is associated with 458 459 changes in diet that can result in changes in lipid profiles ⁶².

460

Genes specifically upregulated in liver tissue were also enriched for specific nociplastic type pain genes. Gene findings from TWAS in this study in theory most likely represent gene expression mediating the relationship between genotype and trait – in other words gene expression that is likely genetically regulated and that occurs before development of nociplastic pain. Therefore, changes in the liver associated with nociplastic pain may develop prior to nociplastic pain development.

23

468 Curcuminoids (components of turmeric) have been previously investigated in treatment 469 of neuropathic pain, and previous studies found that a possible mechanism of action in alleviating neuropathic pain was via modulating nitrogen metabolism ⁶³. Although 470 471 ME/CFS summary statistics were not used in this analysis, changes in nitrogen metabolism have been implicated in this condition ⁶⁴, and our findings suggest these 472 473 metabolic changes may not be unique to ME/CFS but instead shared across COPCs 474 through influence on nociplastic pain in particular. Those with ME/CFS have also been 475 found to have altered lipid, acylcarnitine, and amino acid levels compared to non-ME/CFS controls ⁶⁵. 476 477 478 Positional gene sets enriched for nociplastic type pain genes suggest immune 479 and musculoskeletal factors 480 Positional gene sets associated with specific nociplastic pain genes have also been previously linked to COVID-19 susceptibility and severity (chr3p21, ⁶⁶), schizophrenia 481 and bipolar disorder (chr3p21, ⁶⁷), and Alzheimer disease in an African American cohort 482 (chr3p21,⁷). Regions in chr9q33 are frequently deleted in certain cancers ^{68,69}, and 483 484 chr16q22 has been previously associated with a rare duplication syndrome accompanied by varying psychiatric disorder symptoms ⁷⁰, and with schizophrenia ⁷¹. A 485 486 type of syndactyly (involving fusion of digits and toes) has been associated with chr2q34 ⁷², along with autoimmunity, amyotrophic lateral sclerosis and schizophrenia ⁷³, and 487 age-related degeneration in the lumbar spine ⁷⁴. Variants in the chr12q13 region have 488 been associated with childhood obesity ⁷⁵ and asthma ^{76,77}. Finally, chr1q21 has been 489 previously implicated in GWAS of circulating interleukin 6 levels ⁷⁸. These findings 490

24

suggest shared immune and musculoskeletal related etiology in these phenotypes and
nociplastic type pain. Other recent studies in the context of pain and long COVID have
found that infection can potentially trigger and/or exacerbate existing painful conditions,
particularly COPCs including fibromyalgia and ME/CFS, and that those with an existing
COPC were more likely to develop long COVID, again suggesting possible immune
differences in COPCs ⁷⁹.

497

498 In contrast, positional gene sets enriched for non-specific nociplastic pain genes

499 included chr17q21, where duplication and deletion have previously been associated

500 with syndromes involving distinctive craniofacial features, developmental delay, and

501 cardiac symptoms (Online Mendelian Inheritance in Man (OMIM) accession: 610443,

502 613533), and genes at chr6q16 with cardiac phenotypes ⁸⁰ and cluster headache and 503 migraine ⁸¹.

504 Tissue enrichment of nociplastic type pain genes highlights thyroid, heart, and

505 tibial nerve involvement

Hypothyroidism can both cause pain and worsen pain experienced as part of comorbid
chronic pain conditions. Autoimmune disorders including autoimmune hypothyroidism
may also be misdiagnosed as fibromyalgia ^{82–84}. Enrichment of nociplastic type pain
gene associations in thyroid may therefore indicate high levels of thyroid involvement in
COPCs, or extensive presence of individuals with comorbid (or misdiagnosed)
hypothyroidism among COPC GWAS participants, or both.

25

Atrial appendages of the heart (left and right) are small pouches located on the front 513 514 upper surface of the right atrium, and anterior to the left atrium and parallel to the left 515 pulmonary veins. Atrial fibrillation, the most common abnormal heart rhythm in adults, 516 can lead to formation of clots (most commonly in the left atrial appendage) and subsequent stroke ^{85–87}. Electrocardiogram abnormalities, particularly atrial fibrillation, 517 have been linked to chronic pain ^{88,89}, and with physiological stress associated with 518 chronic illness and major surgery ^{90,91}. Chronic pain has also been associated with 519 520 higher risk of myocardial infarction, death due to cardiovascular event, heart failure, and 521 stroke ⁹². Our findings may suggest this atrial fibrillation in particular could be common 522 in nociplastic pain and COPCs, increasing risk for stroke in these patient populations. 523 524 The tibial nerve is one of two terminal branches of the sciatic nerve, providing motor and 525 sensory innervation to almost all of the posterior foot and leg. An ultrasound study 526 comparing participants with fibromyalgia and controls found significant increased crosssectional area in several nerves, including tibial nerve ⁹³. Tarsal tunnel syndrome, a 527 528 nerve entrapment syndrome analogous to carpal tunnel syndrome in the wrist, was also found to be more common in fibromyalgia patients ⁹⁴ – while causes of tarsal tunnel 529

530 syndrome are likely multifactorial, enlarged tibial nerve diameter may contribute to this

531 nerve entrapment. Neuromodulation involving the tibial nerve (e.g., through

532 percutaneous tibial nerve stimulation) has also been investigated in the treatment of a

range of pelvic pain disorders, including IBS, dysmenorrhea, and bladder pain

534 syndrome ⁹⁵. One caveat is that tibial nerve is the only peripheral nerve tissue sampled

535 in GTEx – other peripheral nerve tissues, potentially also representing therapeutic

26

targets in neuromodulation for chronic pain, could potentially be enriched for nociplasticpain gene expression.

538

539 **Conclusions**

540 COPCs are a subset of chronic pain conditions that are commonly comorbid. A third 541 mechanistic pain descriptor, nociplastic pain, may best represent the pain experience of 542 those with COPCs, where tissue and/or nerve damage is often not present. Using 543 existing COPC GWAS data and a network-informed genomics approach, GenomicSEM, 544 we found genetic variation at the SNP, gene expression, and gene-set level associated 545 with nociplastic type pain. We also explored genetic overlap with other chronic pain 546 phenotypes, tissue enrichment of nociplastic pain genes, and differences in genes 547 specific and non-specific to nociplastic-type pain. Our findings indicate distinct 548 pathology in migraine and headache compared to other COPCs and link this distinct 549 pathology with traits such as Parkinson disease, sense of smell, and androgenic 550 alopecia, as well as provide unique genes associated with this pathology. We 551 demonstrate various degrees of genetic overlap between nociplastic type pain and three 552 different pain traits, showing highest overlap with a trait capturing increasing number of 553 pain sites on the body (a key characteristic of nociplastic pain in the literature), and 554 lowest with rheumatoid arthritis, a chronic pain condition where pain mechanisms are 555 considered mostly nociceptive. We also find tissue enrichment relevant to chronic pain 556 comorbidities including stroke and therapies such as peripheral nerve stimulation. Our findings contribute to further understanding mechanisms of nociplastic type pain, and 557 558 indicate this type of pain is important across COPCs.

27

560 Supplemental Information

561 Supplemental information includes 10 tables.

562 **Declaration of Interests**

563 The authors declare no competing interests.

564 Acknowledgements

- 565 KJAJ is supported by NIMH (R01MH118278; R01MH124839). RS and LMH are
- supported by NIMH (R01MH118278; R01MH124839) and NIEHS (R01ES033630). Data
- 567 associated with UK Biobank approved application number 18177 was used in this study.
- 568 We thank the study authors who provided their GWAS summary statistics directly to us.

569Web Resources

- 570 FUMA: https://fuma.ctglab.nl/
- 571 FUSION and genes tested per tissue: <u>http://gusevlab.org/projects/fusion/#gtex-v8-multi-</u>
- 572 <u>tissue-expression</u>
- 573 GenomicSEM: <u>https://github.com/GenomicSEM/GenomicSEM</u>
- 574 GWASCatalog: https://www.ebi.ac.uk/gwas/
- 575 LDSC: https://github.com/bulik/ldsc
- 576 Data and Code Availability
- 577 Individual-level data for UK Biobank is available upon approved application to UK
- 578 Biobank. Code and resources to implement FUSION, GenomicSEM and LDSC are
- 579 available at the provided web addresses.
- 580 Common-factor GWAS and multivariate TWAS summary statistics produced as part of
- this study are available for download <u>https://doi.org/10.5281/zenodo.8117582</u>

- 582 GWAS summary statistics for broad headache, LBP, and neuropathic pain may be
- 583 available upon request to the respective study authors.
- 584 GWAS summary statistics for endometriosis are available from
- 585 <u>https://www.finngen.fi/en/access_results</u>
- 586 GWAS summary statistics for CWP are available from
- 587 https://zenodo.org/record/4459546
- 588 GWAS summary statistics for IBS are available from
- 589 http://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST90044001-
- 590 <u>GCST90045000/GCST90044107/</u>
- 591 GWAS summary statistics for TMJ are available from
- 592 <u>http://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST90016001-</u>
- 593 <u>GCST90017000/GCST90016564/</u>
- 594
- 595
- 596

29

597 **References**

- Mills, S.E.E., Nicolson, K.P., and Smith, B.H. (2019). Chronic pain: a review of its
 epidemiology and associated factors in population-based studies. Br. J. Anaesth. *123*, e273–
 e283. 10.1016/j.bja.2019.03.023.
- Rahman, M.S., Winsvold, B.S., Chavez Chavez, S.O., Børte, S., Tsepilov, Y.A., Sharapov,
 S.Z., HUNT All-In Pain, Aulchenko, Y.S., Hagen, K., Fors, E.A., et al. (2021). Genomewide association study identifies *RNF123* locus as associated with chronic widespread
 musculoskeletal pain. Ann. Rheum. Dis. 80, 1227–1235. 10.1136/annrheumdis-2020219624.
- Johnston, K.J.A., Adams, M.J., Nicholl, B.I., Ward, J., Strawbridge, R.J., Ferguson, A.,
 McIntosh, A.M., Bailey, M.E.S., and Smith, D.J. (2019). Genome-wide association study of
 multisite chronic pain in UK Biobank. PLOS Genet. *15*, e1008164.
 10.1371/journal.pgen.1008164.
- 4. Tsepilov, Y.A., Freidin, M.B., Shadrina, A.S., Sharapov, S.Z., Elgaeva, E.E., Zundert, J. van,
 Karssen, L.C., Suri, P., Williams, F.M.K., and Aulchenko, Y.S. (2020). Analysis of
 genetically independent phenotypes identifies shared genetic factors associated with chronic
 musculoskeletal pain conditions. Commun. Biol. *3*, 329. 10.1038/s42003-020-1051-9.
- 5. Johnston, K.J.A., Ward, J., Ray, P.R., Adams, M.J., McIntosh, A.M., Smith, B.H.,
 Strawbridge, R.J., Price, T.J., Smith, D.J., Nicholl, B.I., et al. (2021). Sex-stratified genomewide association study of multisite chronic pain in UK Biobank. PLOS Genet. *17*, e1009428.
 10.1371/journal.pgen.1009428.
- 6. Farrell, S.F., Campos, A.I., Kho, P.-F., de Zoete, R.M.J., Sterling, M., Rentería, M.E., Ngo,
 T.T., and Cuéllar-Partida, G. (2021). Genetic basis to structural grey matter associations with
 chronic pain. Brain J. Neurol. *144*, 3611–3622. 10.1093/brain/awab334.
- 621 7. Ghani, M., Reitz, C., Cheng, R., Vardarajan, B.N., Jun, G., Sato, C., Naj, A., Rajbhandary,
 622 R., Wang, L.-S., Valladares, O., et al. (2015). Association of Long Runs of Homozygosity
 623 With Alzheimer Disease Among African American Individuals. JAMA Neurol. 72, 1313–
 624 1323. 10.1001/jamaneurol.2015.1700.
- 8. Nicholas, M., Vlaeyen, J.W.S., Rief, W., Barke, A., Aziz, Q., Benoliel, R., Cohen, M., Evers,
 S., Giamberardino, M.A., Goebel, A., et al. (2019). The IASP classification of chronic pain
 for ICD-11: chronic primary pain. Pain *160*, 28–37. 10.1097/j.pain.00000000001390.
- Freede, R.-D., Rief, W., Barke, A., Aziz, Q., Bennett, M.I., Benoliel, R., Cohen, M., Evers,
 S., Finnerup, N.B., First, M.B., et al. (2019). Chronic pain as a symptom or a disease: the
 IASP Classification of Chronic Pain for the International Classification of Diseases (ICD11). Pain *160*, 19–27. 10.1097/j.pain.00000000001384.
- 632 10. IASP Announces Revised Definition of Pain Int. Assoc. Study Pain IASP. https://www.iasp 633 pain.org/publications/iasp-news/iasp-announces-revised-definition-of-pain/.

- 11. Yong, R.J., Mullins, P.M., and Bhattacharyya, N. (2022). Prevalence of chronic pain among
 adults in the United States. PAIN *163*, e328. 10.1097/j.pain.00000000002291.
- 636 12. Global, regional, and national burden of 12 mental disorders in 204 countries and territories,
 637 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 (2022).
 638 Lancet Psychiatry 9, 137–150. 10.1016/S2215-0366(21)00395-3.
- 639 13. Terminology | International Association for the Study of Pain Int. Assoc. Study Pain IASP.
 640 https://www.iasp-pain.org/resources/terminology/.
- 641 14. Fitzcharles, M.-A., Cohen, S.P., Clauw, D.J., Littlejohn, G., Usui, C., and Häuser, W. (2021).
 642 Nociplastic pain: towards an understanding of prevalent pain conditions. The Lancet *397*,
 643 2098–2110. 10.1016/S0140-6736(21)00392-5.
- Maixner, W., Fillingim, R.B., Williams, D.A., Smith, S.B., and Slade, G.D. (2016).
 Overlapping Chronic Pain Conditions: Implications for Diagnosis and Classification. J. Pain 17, T93–T107. 10.1016/j.jpain.2016.06.002.
- 647 16. Schrepf, A., Phan, V., Clemens, J.Q., Maixner, W., Hanauer, D., and Williams, D.A. (2020).
 648 ICD-10 Codes for the Study of Chronic Overlapping Pain Conditions in Administrative
 649 Databases. J. Pain 21, 59–70. 10.1016/j.jpain.2019.05.007.
- 17. Till, S.R., Schrepf, A., Clauw, D.J., Harte, S.E., Williams, D.A., and As-Sanie, S. (2023).
 Association Between Nociplastic Pain and Pain Severity and Impact in Women With
 Chronic Pelvic Pain. J. Pain, S1526-5900(23)00369-3. 10.1016/j.jpain.2023.03.004.
- 18. Harte, S.E., Harris, R.E., and Clauw, D.J. (2018). The neurobiology of central sensitization.
 J. Appl. Biobehav. Res. 23, e12137. 10.1111/jabr.12137.
- 19. Schrepf, A., Gallop, R., Naliboff, B., Harte, S.E., Afari, N., Lai, H.H., Pontari, M.,
 McKernan, L.C., Strachan, E., Kreder, K.J., et al. (2022). Clinical Phenotyping for Pain
 Mechanisms in Urologic Chronic Pelvic Pain Syndromes: A MAPP Research Network
 Study. J. Pain 23, 1594–1603. 10.1016/j.jpain.2022.03.240.
- 659 20. Jr, L., Da, W., Ms, L., Dj, C., Bd, N., Na, R., A, van B., S, S., Aj, S., Lv, R., et al. (2014).
 660 The MAPP research network: design, patient characterization and operations. BMC Urol. *14*.
 661 10.1186/1471-2490-14-58.
- 21. Neblett, R., Cohen, H., Choi, Y., Hartzell, M., Williams, M., Mayer, T.G., and Gatchel, R.J.
 (2013). THE CENTRAL SENSITIZATION INVENTORY (CSI): ESTABLISHING
 CLINICALLY-SIGNIFICANT VALUES FOR IDENTIFYING CENTRAL SENSITIVITY
 SYNDROMES IN AN OUTPATIENT CHRONIC PAIN SAMPLE. J. Pain Off. J. Am. Pain
 Soc. 14, 438–445. 10.1016/j.jpain.2012.11.012.
- 667 22. Ghavidel Parsa, B., Bidari, A., Atrkarroushan, Z., and Khosousi, M. (2021). Implication of
 668 the Nociplastic Features for Clinical Diagnosis of Fibromyalgia: Development of the
 669 Preliminary Nociplastic Based Fibromyalgia Features (NFF) Tool. ACR Open Rheumatol.
 670 4, 260–268. 10.1002/acr2.11390.

- 671 23. Perugino, F., De Angelis, V., Pompili, M., and Martelletti, P. (2022). Stigma and Chronic
 672 Pain. Pain Ther. 10.1007/s40122-022-00418-5.
- 673 24. Bean, D.J., Dryland, A., Rashid, U., and Tuck, N.L. (2022). The Determinants and Effects of
 674 Chronic Pain Stigma: A Mixed Methods Study and the Development of a Model. J. Pain 23,
 675 1749–1764. 10.1016/j.jpain.2022.05.006.
- 676 25. Collier, R. (2018). "Complainers, malingerers and drug-seekers" the stigma of living with
 677 chronic pain. Can. Med. Assoc. J. *190*, E204–E205. 10.1503/cmaj.109-5553.
- 678 26. De Ruddere, L., and Craig, K.D. (2016). Understanding stigma and chronic pain: a-state-of679 the-art review. Pain *157*, 1607–1610. 10.1097/j.pain.0000000000512.
- 680 27. Quintner, J. (2020). Why Are Women with Fibromyalgia so Stigmatized? Pain Med. 21,
 681 882–888. 10.1093/pm/pnz350.
- 28. Wakefield, E.O., Belamkar, V., Litt, M.D., Puhl, R.M., and Zempsky, W.T. (2021). "There's Nothing Wrong With You": Pain-Related Stigma in Adolescents With Chronic Pain. J.
 Pediatr. Psychol. 47, 456–468. 10.1093/jpepsy/jsab122.
- 685 29. Jackson, J.E. (2005). Stigma, liminality, and chronic pain: Mind-body borderlands. Am.
 686 Ethnol. *32*, 332–353. 10.1525/ae.2005.32.3.332.
- 30. Wakefield, E.O., Kissi, A., Mulchan, S.S., Nelson, S., and Martin, S.R. (2022). Pain-related
 stigma as a social determinant of health in diverse pediatric pain populations. Front. Pain
 Res. 3.
- 31. Samulowitz, A., Gremyr, I., Eriksson, E., and Hensing, G. (2018). "Brave Men" and
 "Emotional Women": A Theory-Guided Literature Review on Gender Bias in Health Care
 and Gendered Norms towards Patients with Chronic Pain. Pain Res. Manag. 2018, 6358624.
 10.1155/2018/6358624.
- 32. Nijs, J., Lahousse, A., Kapreli, E., Bilika, P., Saraçoğlu, İ., Malfliet, A., Coppieters, I., De
 Baets, L., Leysen, L., Roose, E., et al. (2021). Nociplastic Pain Criteria or Recognition of
 Central Sensitization? Pain Phenotyping in the Past, Present and Future. J. Clin. Med. *10*,
 3203. 10.3390/jcm10153203.
- Marcianò, G., Vocca, C., Evangelista, M., Palleria, C., Muraca, L., Galati, C., Monea, F.,
 Sportiello, L., De Sarro, G., Capuano, A., et al. (2023). The Pharmacological Treatment of
 Chronic Pain: From Guidelines to Daily Clinical Practice. Pharmaceutics *15*, 1165.
 10.3390/pharmaceutics15041165.
- 34. Suri, P., Stanaway, I.B., Zhang, Y., Freidin, M.B., Tsepilov, Y.A., Carrell, D.S., Williams,
 F.M.K., Aulchenko, Y.S., Hakonarson, H., Namjou, B., et al. (2021). Genome-wide
 association studies of low back pain and lumbar spinal disorders using electronic health
 record data identify a locus associated with lumbar spinal stenosis. Pain *Publish Ahead of Print*. 10.1097/j.pain.0000000002221.

707 708 709 710	35.	Meng, W., Adams, M.J., Hebert, H.L., Deary, I.J., McIntosh, A.M., and Smith, B.H. (2018). A Genome-Wide Association Study Finds Genetic Associations with Broadly-Defined Headache in UK Biobank (N = 223,773). EBioMedicine 28, 180–186. 10.1016/j.ebiom.2018.01.023.
711 712 713	36.	Jiang, L., Zheng, Z., Fang, H., and Yang, J. (2021). A generalized linear mixed model association tool for biobank-scale data. Nat. Genet. <i>53</i> , 1616–1621. 10.1038/s41588-021-00954-4.
714 715 716 717	37.	Eijsbouts, C., Zheng, T., Kennedy, N.A., Bonfiglio, F., Anderson, C.A., Moutsianas, L., Holliday, J., Shi, J., Shringarpure, S., 23andMe Research Team, et al. (2021). Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. Nat. Genet. <i>53</i> , 1543–1552. 10.1038/s41588-021-00950-8.
718 719 720 721	38.	Hajdarevic, R., Lande, A., Mehlsen, J., Rydland, A., Sosa, D.D., Strand, E.B., Mella, O., Pociot, F., Fluge, Ø., Lie, B.A., et al. (2022). Genetic association study in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) identifies several potential risk loci. Brain. Behav. Immun. <i>102</i> , 362–369. 10.1016/j.bbi.2022.03.010.
722 723 724 725	39.	Grotzinger, A.D., Rhemtulla, M., de Vlaming, R., Ritchie, S.J., Mallard, T.T., Hill, W.D., Ip, H.F., Marioni, R.E., McIntosh, A.M., Deary, I.J., et al. (2019). Genomic structural equation modelling provides insights into the multivariate genetic architecture of complex traits. Nat. Hum. Behav. <i>3</i> , 513–525. 10.1038/s41562-019-0566-x.
726 727 728	40.	Bulik-Sullivan, B., Finucane, H.K., Anttila, V., Gusev, A., Day, F.R., Loh, PR., Duncan, L., Perry, J.R.B., Patterson, N., Robinson, E.B., et al. (2015). An atlas of genetic correlations across human diseases and traits. Nat. Genet. <i>47</i> , 1236–1241. 10.1038/ng.3406.
729 730 731 732	41.	2.1 Calculating Sum of Effective Sample Size and Preparing GWAS Summary Statistics · GenomicSEM/GenomicSEM Wiki · GitHub https://github.com/GenomicSEM/GenomicSEM/wiki/2.1-Calculating-Sum-of-Effective- Sample-Size-and-Preparing-GWAS-Summary-Statistics.
733 734 735	42.	Watanabe, K., Taskesen, E., van Bochoven, A., and Posthuma, D. (2017). Functional mapping and annotation of genetic associations with FUMA. Nat. Commun. <i>8</i> , 1826. 10.1038/s41467-017-01261-5.
736 737 738 739	43.	Bulik-Sullivan, B.K., Loh, PR., Finucane, H.K., Ripke, S., Yang, J., Patterson, N., Daly, M.J., Price, A.L., and Neale, B.M. (2015). LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet. <i>47</i> , 291–295. 10.1038/ng.3211.
740 741 742	44.	ten Klooster, P.M., de Graaf, N., and Vonkeman, H.E. (2019). Association between pain phenotype and disease activity in rheumatoid arthritis patients: a non-interventional, longitudinal cohort study. Arthritis Res. Ther. <i>21</i> , 257. 10.1186/s13075-019-2042-4.

- 45. Cao, Y., Fan, D., and Yin, Y. (2020). Pain Mechanism in Rheumatoid Arthritis: From
 Cytokines to Central Sensitization. Mediators Inflamm. 2020, 2076328.
 10.1155/2020/2076328.
- Veluchamy, A., Hébert, H.L., van Zuydam, N.R., Pearson, E.R., Campbell, A., Hayward, C.,
 Meng, W., McCarthy, M.I., Bennett, D.L.H., Palmer, C.N.A., et al. (2021). Association of
 Genetic Variant at Chromosome 12q23.1 With Neuropathic Pain Susceptibility. JAMA
 Netw. Open 4, e2136560. 10.1001/jamanetworkopen.2021.36560.
- 47. Ha, E., Bae, S.-C., and Kim, K. (2021). Large-scale meta-analysis across East Asian and
 European populations updated genetic architecture and variant-driven biology of rheumatoid
 arthritis, identifying 11 novel susceptibility loci. Ann. Rheum. Dis. 80, 558–565.
 10.1136/annrheumdis-2020-219065.
- 48. Sollis, E., Mosaku, A., Abid, A., Buniello, A., Cerezo, M., Gil, L., Groza, T., Güneş, O.,
 Hall, P., Hayhurst, J., et al. (2023). The NHGRI-EBI GWAS Catalog: knowledgebase and
 deposition resource. Nucleic Acids Res. *51*, D977–D985. 10.1093/nar/gkac1010.

49. Gusev, A., Ko, A., Shi, H., Bhatia, G., Chung, W., Penninx, B.W.J.H., Jansen, R., de Geus,
E.J., Boomsma, D.I., Wright, F.A., et al. (2016). Integrative approaches for large-scale
transcriptome-wide association studies. Nat. Genet. 48, 245–252. 10.1038/ng.3506.

- 50. The GTEx Consortium atlas of genetic regulatory effects across human tissues (2020). 15.
- 761 51. TWAS / FUSION http://gusevlab.org/projects/fusion/#download-pre-computed-predictive 762 models.
- 52. Kosek, E., Clauw, D., Nijs, J., Baron, R., Gilron, I., Harris, R.E., Mico, J.-A., Rice, A.S.C.,
 and Sterling, M. (2021). Chronic nociplastic pain affecting the musculoskeletal system:
 clinical criteria and grading system. PAIN *162*, 2629. 10.1097/j.pain.00000000002324.
- 53. Bailly, F., Cantagrel, A., Bertin, P., Perrot, S., Thomas, T., Lansaman, T., Grange, L.,
 Wendling, D., Dovico, C., and Trouvin, A.-P. (2020). Part of pain labelled neuropathic in
 rheumatic disease might be rather nociplastic. RMD Open *6*, e001326. 10.1136/rmdopen2020-001326.
- 54. Woods, R.H. (2022). Alopecia signals associated with calcitonin gene-related peptide
 inhibitors in the treatment or prophylaxis of migraine: A pharmacovigilance study.
 Pharmacother. J. Hum. Pharmacol. Drug Ther. 42, 758–767. 10.1002/phar.2725.
- 55. Aroke, E.N., and Powell-Roach, K.L. (2020). The Metabolomics of Chronic Pain
 Conditions: A Systematic Review. Biol. Res. Nurs. 22, 458–471.
 10.1177/1099800420941105.
- 56. Boyd, J.T., LoCoco, P.M., Furr, A.R., Bendele, M.R., Tram, M., Li, Q., Chang, F.-M.,
 Colley, M.E., Samenuk, G.M., Arris, D.A., et al. (2021). Elevated dietary ω-6
 polyunsaturated fatty acids induce reversible peripheral nerve dysfunction that exacerbates
 comorbid pain conditions. Nat. Metab. *3*, 762–773. 10.1038/s42255-021-00410-x.

780	57. Chiurchiù, V., Leuti, A., and Maccarrone, M. (2018). Bioactive Lipids and Chronic
781	Inflammation: Managing the Fire Within. Front. Immunol. 9.

- 58. Li, S., Gao, D., and Jiang, Y. (2019). Function, Detection and Alteration of Acylcarnitine
 Metabolism in Hepatocellular Carcinoma. Metabolites *9*, 36. 10.3390/metabo9020036.
- 59. Sanders, A.E., Weatherspoon, E.D., Ehrmann, B.M., Soma, P.S., Shaikh, S.R., Preisser, J.S.,
 Ohrbach, R., Fillingim, R.B., and Slade, G.D. (2022). Circulating polyunsaturated fatty
 acids, pressure pain thresholds, and nociplastic pain conditions. Prostaglandins Leukot.
 Essent. Fatty Acids *184*, 102476. 10.1016/j.plefa.2022.102476.
- 60. Navia-Pelaez, J.M., Choi, S.-H., dos Santos Aggum Capettini, L., Xia, Y., Gonen, A.,
 Agatisa-Boyle, C., Delay, L., Gonçalves dos Santos, G., Catroli, G.F., Kim, J., et al. (2021).
 Normalization of cholesterol metabolism in spinal microglia alleviates neuropathic pain. J.
 Exp. Med. 218, e20202059. 10.1084/jem.20202059.
- Robinson, G., Pineda-Torra, I., Ciurtin, C., and Jury, E.C. (2022). Lipid metabolism in
 autoimmune rheumatic disease: implications for modern and conventional therapies. J. Clin.
 Invest. *132*. 10.1172/JCI148552.
- 62. Elma, Ö., Brain, K., and Dong, H.-J. (2022). The Importance of Nutrition as a Lifestyle
 Factor in Chronic Pain Management: A Narrative Review. J. Clin. Med. *11*, 5950.
 10.3390/jcm11195950.
- Kiang, C., Chen, C., Li, X., Wu, Y., Xu, Q., Wen, L., Xiong, W., Liu, Y., Zhang, T., Dou,
 C., et al. (2022). Computational approach to decode the mechanism of curcuminoids against
 neuropathic pain. Comput. Biol. Med. *147*, 105739. 10.1016/j.compbiomed.2022.105739.
- 64. Armstrong, C.W., McGregor, N.R., Butt, H.L., and Gooley, P.R. (2014). Chapter Five Metabolism in Chronic Fatigue Syndrome. In Advances in Clinical Chemistry, G. S.
 Makowski, ed. (Elsevier), pp. 121–172. 10.1016/B978-0-12-801401-1.00005-0.
- 65. Hoel, F., Hoel, A., Pettersen, I.K.N., Rekeland, I.G., Risa, K., Alme, K., Sørland, K., Fosså,
 A., Lien, K., Herder, I., et al. A map of metabolic phenotypes in patients with myalgic
 encephalomyelitis/chronic fatigue syndrome. JCI Insight 6, e149217.
 10.1172/jci.insight.149217.
- 66. Shelton, J.F., Shastri, A.J., Ye, C., Weldon, C.H., Filshtein-Sonmez, T., Coker, D., Symons,
 A., Esparza-Gordillo, J., Aslibekyan, S., and Auton, A. (2021). Trans-ancestry analysis
 reveals genetic and nongenetic associations with COVID-19 susceptibility and severity. Nat.
 Genet. 53, 801–808. 10.1038/s41588-021-00854-7.
- 67. Yang, Z., Zhou, D., Li, H., Cai, X., Liu, W., Wang, L., Chang, H., Li, M., and Xiao, X.
 (2020). The genome-wide risk alleles for psychiatric disorders at 3p21.1 show convergent
 effects on mRNA expression, cognitive function, and mushroom dendritic spine. Mol.
 Psychiatry 25, 48–66. 10.1038/s41380-019-0592-0.

- 68. Mei, Q., Li, X., Zhang, K., Wu, Z., Li, X., Meng, Y., Guo, M., Luo, G., Fu, X., and Han, W.
 (2017). Genetic and Methylation-Induced Loss of miR-181a2/181b2 within chr9q33.3
 Facilitates Tumor Growth of Cervical Cancer through the PIK3R3/Akt/FoxO Signaling
 Pathway. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 23, 575–586. 10.1158/10780432.CCR-16-0303.
- 69. Ortiz, M., Towfic, F., Flynt, E., Stong, N., Lata, S., Sampath, D., Rozelle, D., Trotter, M.,
 Corre, J., Avet-Loiseau, H., et al. (2019). Gene Expression and Genomic Markers Identify a
 Subpopulation of Poor Prognosis t(4;14) Patients in Newly Diagnosed Multiple Myeloma.
 Blood *134*, 366. 10.1182/blood-2019-128907.
- 70. Gunther, K., Mowrey, K., and Farach, L.S. (2021). Two new reported cases of 16q22.3q23.3
 duplication syndrome highlight intrafamilial variability and potential sex expression
 differences within a rare duplication syndrome. Clin. Case Rep. *9*, 1629–1633.
 10.1002/ccr3.3862.
- 829 71. Bozorgmehr, A., Sadeghi, B., Tabatabaei Zavari, E.S., Bahrami, E., Zamani, F., and
 830 Shahbazi, A. (2020). An integrative gene network-based approach to uncover the cellular
 831 and molecular infrastructures of schizophrenia. Life Sci. 260, 118345.
 832 10.1016/j.lfs.2020.118345.
- 72. Ahmed, H., Akbari, H., Emami, A., and Akbari, M.R. (2017). Genetic Overview of
 Syndactyly and Polydactyly. Plast. Reconstr. Surg. Glob. Open *5*, e1549.
 10.1097/GOX.0000000001549.
- Kao, C.,
 Kao, C.,
 Kao, Z., Bradfield, J., et al. (2020). Rare copy number variants in over 100,000 European
 ancestry subjects reveal multiple disease associations. Nat. Commun. *11*, 255.
 10.1038/s41467-019-13624-1.
- 74. Åkesson, K., Tenne, M., Gerdhem, P., Luthman, H., and McGuigan, F.E. (2015). Variation
 in the PTH2R gene is associated with age-related degenerative changes in the lumbar spine.
 J. Bone Miner. Metab. *33*, 9–15. 10.1007/s00774-013-0550-x.
- 843 75. LITTLETON, S.H., BRADFIELD, J., PIPPIN, J.A., SU, C., CHESI, A., WELLS, A.D.,
 844 BERKOWITZ, R.I., PAHL, M.C., and GRANT, S.F. (2022). 298-OR: Variant-to-Gene
 845 Mapping at the Childhood Obesity Locus on chr12q13 and Subsequent Luciferase Assay
 846 Analyses Implicate rs71329as a Causal Variant within the 3' UTR of FAIM2. Diabetes *71*,
 847 298-OR. 10.2337/db22-298-OR.
- 76. Daya, M., Rafaels, N., Brunetti, T.M., Chavan, S., Levin, A.M., Shetty, A., Gignoux, C.R.,
 Boorgula, M.P., Wojcik, G., Campbell, M., et al. (2019). Association study in Africanadmixed populations across the Americas recapitulates asthma risk loci in non-African
 populations. Nat. Commun. *10*, 880. 10.1038/s41467-019-08469-7.
- 77. Demenais, F., Margaritte-Jeannin, P., Barnes, K.C., Cookson, W.O., Altmüller, J., Ang, W.,
 Barr, R.G., Beaty, T.H., Becker, A.B., Beilby, J., et al. (2018). Multiancestry association

36

- study identifies new asthma risk loci that colocalize with immune cell enhancer marks. Nat.
 Genet. 50, 42–53. 10.1038/s41588-017-0014-7.
- 78. CHARGE Inflammation working group, Ahluwalia, T.S., Prins, B.P., Abdollahi, M.,
 Armstrong, N.J., Aslibekyan, S., Bain, L., Jefferis, B., Baumert, J., Beekman, M., et al.
 (2021). Genome-wide association study of circulating interleukin 6 levels identifies novel
 loci. Hum. Mol. Genet. *30*, 393–409. 10.1093/hmg/ddab023.
- 860 79. Bergmans, R.S., Clauw, D.J., Flint, C., Harris, H., Lederman, S., and Schrepf, A. (2024).
 861 Chronic overlapping pain conditions increase the risk of long COVID features, regardless of
 862 acute COVID status. PAIN *165*, 1112. 10.1097/j.pain.00000000003110.
- 863 80. Wong, D., Auguste, G., Lino Cardenas, C.L., Turner, A.W., Chen, Y., Song, Y., Ma, L.,
 864 Perry, R.N., Aherrahrou, R., Kuppusamy, M., et al. (2023). FHL5 Controls Vascular
 865 Disease-Associated Gene Programs in Smooth Muscle Cells. Circ. Res. *132*, 1144–1161.
 866 10.1161/CIRCRESAHA.122.321692.
- 867 81. O'Connor, E., Fourier, C., Ran, C., Sivakumar, P., Liesecke, F., Southgate, L., Harder,
 868 A.V.E., Vijfhuizen, L.S., Yip, J., Giffin, N., et al. (2021). Genome-Wide Association Study
 869 Identifies Risk Loci for Cluster Headache. Ann. Neurol. *90*, 193–202. 10.1002/ana.26150.
- 870 82. Atzeni, F., Cazzola, M., Benucci, M., Di Franco, M., Salaffi, F., and Sarzi-Puttini, P. (2011).
 871 Chronic widespread pain in the spectrum of rheumatological diseases. Best Pract. Res. Clin.
 872 Rheumatol. 25, 165–171. 10.1016/j.berh.2010.01.011.
- 873 83. Häuser, W., Sarzi-Puttini, P., and Fitzcharles, M.-A. (2019). Fibromyalgia syndrome: under-,
 874 over- and misdiagnosis. Clin. Exp. Rheumatol. *37*, 90–97.
- 875 84. Häuser, W., Perrot, S., Sommer, C., Shir, Y., and Fitzcharles, M.-A. (2017). Diagnostic
 876 confounders of chronic widespread pain: not always fibromyalgia. Pain Rep. 2, e598.
 877 10.1097/PR9.0000000000598.
- 878 85. Richardson, A.C., Omar, M., Velarde, G., Missov, E., Percy, R., and Sattiraju, S. (2021).
 879 Right Atrial Appendage Thrombus in Atrial Fibrillation: A Case Report and Review of the
 880 Literature. J. Investig. Med. High Impact Case Rep. 9, 23247096211010048.
 881 10.1177/23247096211010048.
- 882 86. Regazzoli, D., Ancona, F., Trevisi, N., Guarracini, F., Radinovic, A., Oppizzi, M., Agricola,
 883 E., Marzi, A., Sora, N.C., Della Bella, P., et al. (2015). Left Atrial Appendage: Physiology,
 884 Pathology, and Role as a Therapeutic Target. BioMed Res. Int. 2015, 205013.
 885 10.1155/2015/205013.
- 886 87. McIntyre, W.F., and Healey, J. (2017). Stroke Prevention for Patients with Atrial
 887 Fibrillation: Beyond the Guidelines. J. Atr. Fibrillation 9, 1475. 10.4022/jafib.1475.

888 88. Peuckmann-Post, V., Eickhoff, R., Becker, M., and von der Laage, D. (2012). [ECG changes
889 in patients with chronic non-cancer pain: a prospective observational study]. Schmerz Berl.
890 Ger. 26, 419–424. 10.1007/s00482-012-1204-y.

37

891 892 893	 Gong, C., Ding, Y., Liang, F., Wu, S., Tang, X., Ding, H., Huang, W., Yu, X., Zhou, L., Li, J., et al. (2022). Muscarinic receptor regulation of chronic pain-induced atrial fibrillation. Front. Cardiovasc. Med. <i>9</i>, 934906. 10.3389/fcvm.2022.934906.
894 895	 McIntyre, W.F., Connolly, S.J., and Healey, J.S. (2018). Atrial fibrillation occurring transiently with stress. Curr. Opin. Cardiol. 33, 58–65. 10.1097/HCO.000000000000475.
896 897 898 899	91. McIntyre, W.F., Um, K.J., Cheung, C.C., Belley-Côté, E.P., Dingwall, O., Devereaux, P.J., Wong, J.A., Conen, D., Whitlock, R.P., Connolly, S.J., et al. (2019). Atrial fibrillation detected initially during acute medical illness: A systematic review. Eur. Heart J. Acute Cardiovasc. Care 8, 130–141. 10.1177/2048872618799748.
900 901 902	92. Rönnegård, AS., Nowak, C., Äng, B., and Ärnlöv, J. (2022). The association between short-term, chronic localized and chronic widespread pain and risk for cardiovascular disease in the UK Biobank. Eur. J. Prev. Cardiol. <i>29</i> , 1994–2002. 10.1093/eurjpc/zwac127.
903 904 905	93. Di Carlo, M., Bianchi, B., Cipolletta, E., Farah, S., Filippucci, E., and Salaffi, F. Imaging of the peripheral nervous system in nociplastic pain: An ultrasound study in patients with fibromyalgia. J. Neuroimaging <i>n/a</i> . 10.1111/jon.13104.
906 907 908	94. JO, YS., YOON, B., HONG, J.Y., JOUNG, CI., KIM, Y., and NA, SJ. (2021). Tarsal tunnel syndrome in patients with fibromyalgia. Arch. Rheumatol. <i>36</i> , 107–113. 10.46497/ArchRheumatol.2021.7952.
909 910	95. Xiang, H., Zhang, T., Al-Danakh, A., Yang, D., and Wang, L. (2022). Neuromodulation in Chronic Pelvic Pain: A Narrative Review. Pain Ther. <i>11</i> , 789–816. 10.1007/s40122-022-00405 m

911 00405-w.

912

38

914 Figure Titles and Legends

- 915 Figure 1: Path diagram of common factor GWAS GenomicSEM model.
- 916 Values = Standardized Estimate (Standard Error).
- 917 Figure 2: Manhattan plot of nociplastic-type pain common-factor GWAS and

918 multivariate TWAS outputs.

- 919 A: Nociplastic-type pain common-factor GWAS Manhattan plot. Dotted line = genome-
- 920 wide p value significance threshold $(-\log_{10}(5 \times 10^{-8}))$. B: Nociplastic-type pain –
- 921 multivariate TWAS Manhattan plot. X-axis labels = GTEx v8 tissue, points shown in
- 922 orange = gene-tissue associations significant after Bonferroni adjustment within that
- 923 tissue, labeled points = genes with most significant association within that tissue.

924 Figure 3: GWAS catalog trait gene set enrichments.

- 925 A: Gene sets enriched for all nociplastic-type pain genes found in multivariate TWAS
- analysis, B: Gene sets enriched for specific nociplastic type pain genes, Panel C: Gene
- 927 sets enriched for non-specific nociplastic type pain genes.
- 928

Trait	Acronym	Source	Cases	Controls
Chronic widespread pain	CWP	Rahman et al	6914	242929
		2021 ²		
Endometriosis	NA	FinnGenn (R9,	15088	107564
		May 2023)		
Low-back pain	LBP	Suri et al 2021 ³⁴	49182	51629
Broad headache	NA	Meng et al	74461	149312
		2018 ³⁵		
Temporomandibular joint	ТМЈ	Jiang et al 2021	217	456131
disorder		(GWAS		
		Catalog) ³⁶		

Irritable Bowel Syndrome	IBS	Eijsbouts et al	53400	433201
		2021 (GWAS		
		Catalog) ³⁷		

929 **Table 1: Sources and sample sizes for COPC trait GWAS.** See Table S1 for sample

930 and population prevalence estimates and their sources.

931

Trait	Standardized	Standardized	p-value
	Estimate	SE	
CWP	0.76	0.06	1.78x10 ⁻⁴¹
IBS	0.62	0.03	3.87 x10 ⁻⁷³
Broad Headache	0.73	0.04	4.56 x10 ⁻⁸¹
LBP	0.39	0.04	5.53 x10 ⁻²⁸
TMJ	0.69	0.29	0.0188
Endometriosis	0.57	0.06	3.34 x10 ⁻²⁰

932 **Table 2: Standardized common-factor GWAS model factor loadings and p values.**

933 SE = standard error.



Nociplastic-Type Pain: Common-Factor GWAS



В

Α

Nociplastic-Type Pain: Multivariate TWAS

.....



